Arisha Patel, Mounzer Agha, Anastasios Raptis, Jing-Zhou Hou, Rafic Farah, Robert L. Redner, Annie Im, Kathleen A. Dorritie, Alison Sehgal, James Rossetti, Melissa Saul, Daniel Normolle, Konstantinos Lontos, Michael Boyiadzis

Oncology Research, Vol.28, No.7-8, pp. 811-814, 2020, DOI:10.3727/096504020X15965357399750

Abstract Leukemia relapse 5 years after achieving first complete remission (CR1) is uncommon in patients with acute myeloid leukemia (AML). In this study, we evaluated the outcomes of AML patients with late relapse at our institution and reviewed the literature for these patients. The study cohort consisted of nine AML patients with late relapse. The median interval between CR1 and AML relapse was 6.1 years (range: 5.1–16.2 years). At relapse, the karyotype was different from the initial AML diagnosis in 50% of patients. At the time of AML relapse, seven patients received induction chemotherapy and two More >

Annie Im, Ali Amjad, Mounzer Agha, Anastasios Raptis, Jing-Zhou Hou, Rafic Farah, Seah Lim, Alison Sehgal, Kathleen A. Dorritie, Robert L. Redner, Brian McLaughlin, Yongli Shuai, Shrina Duggal, Michael Boyiadzis

Oncology Research, Vol.24, No.2, pp. 73-80, 2016, DOI:10.3727/096504016X14586627440156

Abstract Relapsed acute myeloid leukemia (AML) represents a major therapeutic challenge. Achieving complete remission (CR) with salvage chemotherapy is the first goal of therapy for relapsed AML. However, there is no standard salvage chemotherapy. The current study evaluated outcomes and prognostic factors for achievement of CR in 91 AML patients in first relapse who were treated with the mitoxantrone–etoposide combination regimen. The overall response rate (CR and CRi) was 25%. Factors that were associated with a lower rate of CR included older age, shorter duration of first CR, low hemoglobin, and low platelet count. The median… More >

S. Marwaha, P. M. Venner, S. A. North

Canadian Journal of Urology, Vol.14, No.5, pp. 3692-3696, 2007

Abstract Objective: The primary objective was to evaluate the effect of etoposide dose in a 3-day cisplatin/etoposide/bleomycin (PEB) regimen on progression free survival (PFS) and overall survival (OS). Secondary objectives were to determine the impact of a paclitaxel-based salvage regimen on OS and to compare the risk distribution of germ cell patients seen at a tertiary care center to that quoted in the International Germ Cell Consensus Classification (IGCCC).
Methods: A retrospective chart review of all 302 metastatic germ cell patients requiring cisplatin-based chemotherapy between January 1980 and December 2004 was conducted. Data collected on initial treatment… More >

P. Chung¹, C. Parker¹, T. Panzarella², M. K. Gospodarowicz¹, M.A. S. Jewett³, M. F. Milosevic¹, C. N. Catton¹, A. J. Bayley¹, B. Tew-George, M. Moore⁴, J. F. G. Sturgeon⁴, P. Warde¹

Canadian Journal of Urology, Vol.9, No.5, pp. 1637-1640, 2002

Abstract Introduction: Surveillance is an alternative to adjuvant radiotherapy for stage I testicular seminoma. We present the long-term results of seminoma surveillance, with emphasis on quantifying the risk of late relapse beyond 5 years.
Methods: From 1981 to 1993, of 431 men with stage I testicular seminoma, 203 were managed by surveillance following radical orchidectomy. The surveillance protocol comprised a combination of clinical examination, CT scans of abdomen and pelvis, chest x-rays and serum markers, at defined intervals.
Results: At a median follow-up of 9.2 years, 35 men have relapsed. Five of the relapses occurred more than 5 years… More >